We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-2.95%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$333M
Cap. Flow
-$249M
Cap. Flow %
-22.11%
Top 10 Hldgs %
64.02%
Holding
82
New
15
Increased
14
Reduced
31
Closed
17

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$16.3M
2
BRKR icon
Bruker
BRKR
+$13.9M
3
TFX icon
Teleflex
TFX
+$12.7M
4
PCVX icon
Vaxcyte
PCVX
+$12.7M
5
EW icon
Edwards Lifesciences
EW
+$11.9M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$79.5M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$64.4M
3
UTHR icon
United Therapeutics
UTHR
+$32.1M
4
TECH icon
Bio-Techne
TECH
+$26.7M
5
CYH icon
Community Health Systems
CYH
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
2 Miscellaneous 13.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$47B
$139M 12.32%
876,766
+6,573
+0.8% +$957K
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$489B
$124M 11.03%
243,100
-6,500
-3% -$3.29M
GSK icon
3
GSK
GSK
$102B
$124M 10.99%
3,661,768
-395,438
-10% -$14.2M
VERA icon
4
Vera Therapeutics
VERA
$2.46B
$67.7M 6.01%
1,600,015
-450,142
-22% -$19.9M
INSP icon
5
Inspire Medical Systems
INSP
$1.78B
$54.6M 4.84%
294,302
+18,032
+7% +$3.5M
HCA icon
6
HCA Healthcare
HCA
$90.5B
$52.8M 4.68%
175,808
+46,724
+36% +$16.3M
TEVA icon
7
Teva Pharmaceuticals
TEVA
$42.5B
$49.4M 4.39%
2,242,125
-992,513
-31% -$18.1M
RVTY icon
8
Revvity
RVTY
$14.4B
$43.8M 3.89%
392,518
-77,174
-16% -$9.07M
HQY icon
9
HealthEquity
HQY
$7.97B
$37.1M 3.29%
386,697
+67,619
+21% +$6.3M
ZIMV
10
DELISTED
ZimVie
ZIMV
$28.9M 2.56%
2,070,780
– –
PTGX icon
11
Protagonist Therapeutics
PTGX
$9.34B
$26.2M 2.33%
678,787
+233,583
+52% +$10.2M
TECH icon
12
Bio-Techne
TECH
$11.3B
$21.6M 1.91%
299,310
-364,263
-55% -$26.7M
CLDX icon
13
Celldex Therapeutics
CLDX
$3.07B
$18.2M 1.61%
719,836
+154,934
+27% +$4.21M
SPY icon
14
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$17.5M 1.55%
29,800
-30,200
-50% -$17.8M
VTRS icon
15
Viatris
VTRS
$18.8B
$15.8M 1.41%
1,272,102
-454,252
-26% -$5.58M
TLT icon
16
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$46.8B
$15.7M 1.39%
+179,400
New +$16.5M
UTHR icon
17
United Therapeutics
UTHR
$22.1B
$15.4M 1.37%
43,703
-87,246
-67% -$32.1M
VRDN icon
18
Viridian Therapeutics
VRDN
$2.61B
$15M 1.33%
779,998
+88,766
+13% +$1.93M
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.51B
$14.9M 1.32%
1,980,312
+1,444,907
+270% +$11M
BRKR icon
20
Bruker
BRKR
$8.7B
$13.8M 1.22%
+234,934
New +$13.9M
EW icon
21
Edwards Lifesciences
EW
$52B
$12.6M 1.12%
+170,678
New +$11.9M
DXCM icon
22
DexCom
DXCM
$34.3B
$11.6M 1.03%
+148,688
New +$11M
CNC icon
23
Centene
CNC
$32B
$11.4M 1.01%
188,493
+53,534
+40% +$3.34M
TFX icon
24
Teleflex
TFX
$5.92B
$11M 0.98%
+61,736
New +$12.7M
ELV icon
25
Elevance Health
ELV
$85.5B
$10.8M 0.96%
29,178
+9,713
+50% +$4.06M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Eversept Partners held 82 positions worth $1.13B, down 23% from $1.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Eversept Partners withdrew a net $249M in Q4 2024, closing 17 positions and reducing 31 holdings. Its most notable exit was Insmed, an estimated $79.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Bruker worth $13.8M.

  • Eversept Partners's largest Q4 2024 buy was Bruker: 234,934 shares worth $13.8M.
  • Eversept Partners added most to HCA Healthcare in Q4 2024, an estimated $16.3M increase.
  • Eversept Partners's biggest Q4 2024 reduction was Syndax Pharmaceuticals, cutting an estimated $64.4M.
  • Eversept Partners fully exited Insmed in Q4 2024, selling an estimated $79.5M.
  • Eversept Partners's ten largest holdings make up 64% of its $1.13B portfolio in Q4 2024.
  • Eversept Partners opened 15 new positions and closed 17 in Q4 2024.
  • Eversept Partners's portfolio value fell 23% quarter-over-quarter to $1.13B.

Based on Eversept Partners's 13F filing for Q4 2024, filed 14 Feb 2025.